Supreme Court Takes Pass on Clarifying Patent Eligibility, Disappointing BioPharma
Executive Summary
Industry now needs to wait for a more appealing appeal or a revived legislative effort after the high court declines review of Athena Diagnostics v. Mayo Collaborative Services, which created a sharp divide in the Federal Circuit, and Hikma v. Vanda; biopharma and others contend eligibility issue is biggest problem in patent system.
You may also be interested in...
Patent Eligibility Bill May Carve Out Patenting Of Research
Witnesses at US Senate hearings debate bill's impact on drug pricing; discuss limiting it to medical diagnostics.
Federal Circuit Tosses Diagnostic Patent, Spurring Biopharma Calls For Congressional Action
A divided panel finds Athena Diagnostics' patent on method to diagnose myasthenia gravis is invalid; in dissent, Judge Newman cites industry concerns that the decision will deter development of new diagnostic methods.
Pharma Industry Broadens Its Approach To Expanded Access
Novartis co-leads industry forum on preapproval access that aims to share best practices and engage patient groups; Janssen is launching three pilots to leverage collection of preapproval access data.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: